How Much Weight Per Week Can You Lose on Mounjaro?

Last reviewed: July 12, 2026

Last updated: July 12, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide (marketed as Mounjaro for diabetes, used off-label for weight loss) produces weight reduction through dual GLP-1 and GIP receptor activation—a mechanism stronger than single-agent GLP-1 drugs. Most patients experience gradual, weekly losses that vary based on starting weight, metabolism, diet, and exercise, with accelerated results during the first 12 weeks of treatment.

Average Weekly Weight Loss Rates on Tirzepatide

Clinical trial data from the SURMOUNT series (tirzepatide's pivotal weight-loss trials) documented participants losing 15–22% of their starting body weight over 72 weeks. This translates to roughly 1–2 pounds per week during active dose escalation (weeks 1–16), then 0.5–1.5 pounds weekly during the maintenance phase. Individual weekly loss varies widely—some patients see 2–3 pounds in a single week, while others experience plateaus of 1–2 weeks before resuming loss.

The rate of weight loss is not linear. Most people experience the steepest descent during the first 12 weeks when appetite suppression is building and metabolic adjustment is occurring. After week 16 (when the full maintenance dose is reached), the rate typically stabilizes at a slower but consistent pace. PlexusDx tirzepatide protocols account for this natural pattern and adjust expectations accordingly.

Factors That Influence Your Personal Weekly Loss Rate

Your starting body weight has the largest single impact on weekly loss speed. Patients starting at higher weights (over 250 pounds) commonly lose 2–3 pounds per week initially, while those starting at lower weights may see 0.5–1 pound weekly. Baseline metabolism, age, sex, and muscle mass also shift the equation—a 65-year-old with low muscle mass typically loses weight more slowly than a 35-year-old with an active lifestyle, even at the same tirzepatide dose.

Diet quality, calorie intake, physical activity level, sleep, and stress management directly modulate tirzepatide's effectiveness. The medication suppresses appetite and craving, but it does not force weight loss; users who maintain a high-calorie diet or sedentary lifestyle will lose weight more slowly than those who combine tirzepatide with a modest calorie deficit and regular movement. Alcohol consumption and certain medications (like some antidepressants) can also slow progress.

Understanding the Dose Escalation Schedule and Weight Loss Timing

PlexusDx tirzepatide injection begins at a low starting dose and increases every 4 weeks until reaching your personalized maintenance dose. During weeks 1–4 (starting dose), weight loss is often modest—many patients report 0.5–1 pound per week. Weeks 5–8 (second dose) typically produce faster loss as appetite suppression deepens. Weeks 9–12 (third dose) and weeks 13–16 (final dose escalation) often show the most dramatic weekly losses, sometimes 2–3 pounds per week.

After week 16, when you reach your maintenance dose, the weekly loss rate typically slows to 0.5–1.5 pounds per week because your body adapts to the medication and appetite suppression reaches a plateau. This does not mean progress stops—it means the rate normalizes to a sustainable, long-term pace. PlexusDx pricing remains flat throughout the escalation schedule ($289/mo for compounded tirzepatide injection), so your dose can increase without increasing your cost.

Genetic Insights and Personalized Response Prediction

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Patients carrying certain GLP1R or GIPR variants often experience faster initial weight loss and more robust appetite suppression, while those with specific FTO variants may progress more gradually but achieve comparable total loss over time. Understanding your genetic predisposition helps set realistic expectations and guides whether standard dosing, higher-dose protocols, or dual-compound options (like GLP-Squared) may serve you best. The genetic test costs $99 as an add-on after your first month of treatment.

Comparing Tirzepatide to Other GLP-1 Medications

Tirzepatide's dual mechanism (GLP-1 and GIP) typically produces faster and larger total weight loss than single-agent GLP-1 drugs (like semaglutide). Clinical comparisons show tirzepatide users lose 5–10 pounds more on average over 72 weeks than matched semaglutide cohorts. Weekly loss rates are similarly faster with tirzepatide—often 1.5–2.5 pounds per week at peak efficacy versus 1–1.5 pounds weekly on semaglutide maintenance doses.

PlexusDx offers both compounded tirzepatide injection ($289/mo) and oral tirzepatide ($349/mo), as well as dual-compound GLP-Squared (tirzepatide + semaglutide injection from $289/mo (or $249/mo on the 3-month plan)), providing options if single-agent tirzepatide plateaus or side effects emerge. All medications ship to all 50 states without insurance or membership, with HSA/FSA eligibility for cost savings.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is 1–2 pounds per week realistic for me, or is that too optimistic?

Clinical trials show 1–2 pounds weekly during active dose escalation is realistic for most patients, especially those starting above 250 pounds or with significant metabolic dysfunction. Slower rates (0.5–1 pound weekly) are normal for those starting at lower weights or with complicating factors like low muscle mass or high baseline metabolism. PlexusDx personalizes expectations based on your starting metrics and genetic profile.

Will my weekly weight loss stay at 2 pounds forever, or does it slow down?

Weekly loss typically slows after week 16 when you reach maintenance dose, dropping from 2–3 pounds per week to 0.5–1.5 pounds weekly. This is normal and expected—it reflects metabolic adaptation and appetite-suppression plateau, not treatment failure. Sustained weight loss continues, just at a steadier, more sustainable pace that most patients can maintain long-term.

What if I'm not losing 1–2 pounds per week after 8 weeks on tirzepatide?

Slower-than-expected loss at week 8 may signal suboptimal calorie deficit, medication tolerance, or a genetic profile less responsive to standard dosing. PlexusDx recommends the Precision Peptide Genetic Test ($99 add-on) to assess your peptide-pathway genetics and determine whether higher tirzepatide doses, dual-compound therapy (GLP-Squared), or protocol adjustments suit you better. Many patients respond to dose optimization or lifestyle refinement.

Are there side effects that might slow weight loss or cause stalls?

Gastrointestinal side effects (nausea, constipation, reduced appetite) are most common in weeks 1–6 and typically resolve by week 8–12. During active GI adjustment, some patients reduce food intake so severely that electrolyte imbalance or dehydration slows metabolism temporarily. Once side effects settle, weight loss usually accelerates. Serious adverse events are rare with compounded tirzepatide from licensed 503A pharmacies when prescribed by qualified clinicians.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx Precision Peptide Genetic Test maps 14 metabolic and appetite-regulation pathways, including GLP1R, GIPR, FTO, and MC4R variants, to forecast your tirzepatide responsiveness and likely weekly loss trajectory. Patients with favorable GLP1R or GIPR genotypes often experience faster, steeper losses (1.5–2.5 pounds weekly), while those with other variants may progress steadily but more gradually. The test costs $99 after your first month and is available exclusively to PlexusDx patients.

Related Reading

• Mounjaro Weight Loss By Week
• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.